Vor Biopharma Inc.

Listed Company

VORCIK 0001817229NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)FY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-695.98M

Total Assets

$464.13M

Equity

$-164.31M

Shares Out

54.19M

Op. Cash Flow

$-142.71M

VOR$18.09−62.00% · past yearDBEQ Basic

Daily closing prices

Business

Vor Biopharma is a clinical-stage biopharmaceutical company developing telitacicept, a fusion protein targeting BAFF and APRIL for autoimmune diseases. The company in-licensed telitacicept from RemeGen in June 2025 for exclusive rights outside Greater China, where it is approved for systemic lupus erythematosus, rheumatoid arthritis, and generalized myasthenia gravis. Vor is conducting global Phase 3 trials in generalized myasthenia gravis and Sjögren's disease to support regulatory approvals in the United States, Europe, and Japan. The company relies on third-party contract manufacturers for clinical and commercial supply.

Summary from 10-K filed 2026-03-30

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	322	93	94	65	48
General and administrative	50	28	32	29	21
Total operating expenses	372	121	126	93	69
Loss from operations	−372	−121	−126	−93	−69
Interest income	6	4	8	1	119,000
Other income	4	0	—	—	—
Change in fair value of warrant liabilities	−334	0	—	—	—
Total other income (expense), net	−324	4	8	1	119,000
Net loss	−696	−117	−118	−92	−69
Net loss per share, basic	−70.5	−34.03	−1.75	−2.33	−2.1
Net loss per share, diluted	−70.5	−34.03	−1.75	−2.33	−2.1
Weighted-average common shares outstanding, basic	10	3	67	40	33
Weighted-average common shares outstanding, diluted	10	3	67	40	33
Unrealized gain on available for sale marketable securities	19,000	99,000	693,000	−770,000	—
Total other comprehensive income	19,000	99,000	693,000	−770,000	—
Comprehensive loss	−696	−117	−117	−93	−70

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	396	82	31	58	120
Marketable securities	59	10	106	173	88
Prepaid expenses	1	4	3	4	5
Other current assets	2	380,000	475,000	2	2
Total current assets	458	97	141	237	214
Restricted cash equivalents	200,000	2	2	2	2
Property and equipment, net	533,000	7	10	13	7
Operating lease right-of-use assets	3	35	40	44	16
Other assets	2	2	5	3	3
Total assets	464	143	198	299	243
Accounts payable	5	2	815,000	2	2
Accrued liabilities	20	13	11	8	6
Operating lease liabilities	280,000	4	4	3	2
Total current liabilities	25	19	16	13	10
Operating lease liabilitiesnon-current	3	28	32	36	16
Warrant liabilities	601	0	—	—	—
Total liabilities	628	46	47	49	26
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024	—	—	—	—	—
Common stock, $0.0001 par value; 800,000,000 and 400,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 38,720,196 and 6,238,799 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	18,000	13,000	7,000	7,000	4,000
Additional paid-in capital	989	554	491	474	346
Accumulated other comprehensive income	41,000	22,000	−77,000	−770,000	—
Accumulated deficit	−1,153	−457	−340	−222	−130
Total stockholders' equity (deficit)	−164	97	151	251	216
Total liabilities and stockholders' equity (deficit)	464	143	198	299	243

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−696	−117	−118	−92	−69
Depreciation expense	3	4	4	3	1
Non-cash lease expense	6	5	5	4	3
Stock-based compensation	19	10	13	11	4
Transaction costs for issuance of pre-funded warrants	643,000	0	—	—	—
Interest amortization on marketable securities	−67,000	−1	−5	−12,000	—
Loss (gain) on sale of property and equipment	3	−18,000	—	—	—
Issuance of pre-funded warrants in connection with the acquisition of in-process research and development	177	0	—	—	—
Operating lease liabilities	−2	−4	−4	−10	−3
Prepaid expenses and other current assets	2	−835,000	3	225,000	−6
Accounts payable and accrued liabilities	11	2	3	1	405,000
Other assets	0	2	−2	−721,000	−668,000
Net cash used in operating activities	−143	−100	−100	−85	−69
Purchases of marketable securities	−54	−10	−75	−123	−88
Proceeds from maturities of marketable securities	5	107	147	38	—
Purchases of property and equipment	−941,000	−229,000	−1	−8	−4
Proceeds from sales of property and equipment	799,000	0	—	—	—
Net cash (used in) provided by investing activities	−49	97	71	−94	−92
Proceeds from the issuance of common stock from private placement	150	56	—	—	—
Proceeds from the issuance of common stock from underwritten public offering, net of underwriting discount and commissions	108	0	—	—	—
Proceeds from the issuance of pre-funded warrants	175	0	—	—	—
Payment of issuance costs related to underwritten public offering and private placements	−1	−2	−717,000	—	—
Proceeds from the issuance of common stock from at-the-market sales agreement, net of issuance costs	70	275,000	5	4	—
Withholding of shares for tax withholdings upon vesting of restricted stock unit awards	−254,000	−333,000	−1	—	—
Proceeds from stock option exercises and the issuance of shares under ESPP	2	225,000	264,000	1	—
Net cash provided by financing activities	504	53	3	117	233
Net increase in cash, cash equivalents and restricted cash equivalents	312	51	−26	−62	72
Right-of-use assets obtained in exchange for lease obligations	3	0	—	23	—
Financing costs associated with the sale of common stock included in accounts payable and accrued expenses	127,000	563,000	27,000	812,000	—
Unrealized gain on available-for-sale securities	19,000	99,000	—	—	—
Issuance of pre-funded warrants in connection with the acquisition of in-process research and development	177	0	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Vor Biopharma Inc.'s CIK number?

Vor Biopharma Inc.'s SEC CIK number is 0001817229 (1817229). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Vor Biopharma Inc.'s SEC filings?

All of Vor Biopharma Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Vor Biopharma Inc. last report earnings?

Vor Biopharma Inc. (VOR) most recently filed an earnings 8-K with the SEC on Jan 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-009961). This is Vor Biopharma Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Vor Biopharma Inc.'s most recent earnings 8-K?

Vor Biopharma Inc.'s latest earnings 8-K (Item 2.02) was filed Jan 12, 2026 under accession 0001193125-26-009961. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Vor Biopharma Inc.'s latest earnings 8-K →
Look up any company's CIK number →